TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
AstraZeneca and Amgen's TEZSPIRE met both co-primary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with histologic remission of 64.8% (210mg) and 68.9% (420mg) at week 24 versus 3.5% on placebo. Efficacy was sustained through week 52, and TEZSPIRE also achieved statistically significant improvements in dysphagia symptoms and endoscopic outcomes, with total endoscopic remission in roughly 30-34% of patients at week 52 versus 4.1% on placebo. Safety was consistent with approved indications.
Key figures
- Drug Name
- TEZSPIRE (tezepelumab)
- Phase Of Trial
- Phase 3
- Patients randomized
- 368
- Dsq improvement week52
- -22.1 (210mg) and -24.0 (420mg) vs -13.2 placebo
- Histologic remission week24 210mg
- 64.8%
- Histologic remission week24 420mg
- 68.9%
- Histologic remission week52 210mg
- 67.8%
- Histologic remission week52 420mg
- 63.3%
- Histologic remission week24 placebo
- 3.5%
- Histologic remission week52 placebo
- 5.4%
- Total endoscopic remission week52 210mg
- 34.4%
- Total endoscopic remission week52 420mg
- 29.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.